267 related articles for article (PubMed ID: 20385902)
1. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases.
Krainc D
Arch Neurol; 2010 Apr; 67(4):388-92. PubMed ID: 20385902
[TBL] [Abstract][Full Text] [Related]
2. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
Ciechanover A; Kwon YT
Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
[TBL] [Abstract][Full Text] [Related]
3. Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment?
Lin F; Qin ZH
J Huntingtons Dis; 2013; 2(2):149-57. PubMed ID: 25063512
[TBL] [Abstract][Full Text] [Related]
4. Neurodegenerative disease: Tracking disease progress in Huntington disease.
Barker RA; Mason SL
Nat Rev Neurol; 2011 Apr; 7(4):192-3. PubMed ID: 21403672
[No Abstract] [Full Text] [Related]
5. Paradoxical aggregation versus oligomerisation properties of mutant and wild-type huntingtin fragments.
Rubinsztein DC; Huntington JA
Exp Neurol; 2006 Jun; 199(2):243-4. PubMed ID: 16631742
[No Abstract] [Full Text] [Related]
6. Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.
Harding RJ; Tong YF
Acta Pharmacol Sin; 2018 May; 39(5):754-769. PubMed ID: 29620053
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
8. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.
Maiti P; Manna J; Veleri S; Frautschy S
Biomed Res Int; 2014; 2014():495091. PubMed ID: 25386560
[TBL] [Abstract][Full Text] [Related]
9. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
[TBL] [Abstract][Full Text] [Related]
10. Huntington's disease: degradation of mutant huntingtin by autophagy.
Sarkar S; Rubinsztein DC
FEBS J; 2008 Sep; 275(17):4263-70. PubMed ID: 18637946
[TBL] [Abstract][Full Text] [Related]
11. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
Jiang H; Poirier MA; Liang Y; Pei Z; Weiskittel CE; Smith WW; DeFranco DB; Ross CA
Neurobiol Dis; 2006 Sep; 23(3):543-51. PubMed ID: 16766198
[TBL] [Abstract][Full Text] [Related]
12. Nucleation of huntingtin aggregation in cells.
Wetzel R
Nat Chem Biol; 2006 Jun; 2(6):297-8. PubMed ID: 16710335
[No Abstract] [Full Text] [Related]
13. Polyglutamine disease: acetyltransferases awry.
Hughes RE
Curr Biol; 2002 Feb; 12(4):R141-3. PubMed ID: 11864588
[TBL] [Abstract][Full Text] [Related]
14. Huntington's disease--making connections.
Greenamyre JT
N Engl J Med; 2007 Feb; 356(5):518-20. PubMed ID: 17267914
[No Abstract] [Full Text] [Related]
15. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.
Jia H; Kast RJ; Steffan JS; Thomas EA
Hum Mol Genet; 2012 Dec; 21(24):5280-93. PubMed ID: 22965876
[TBL] [Abstract][Full Text] [Related]
16. Autophagy in Huntington disease and huntingtin in autophagy.
Martin DD; Ladha S; Ehrnhoefer DE; Hayden MR
Trends Neurosci; 2015 Jan; 38(1):26-35. PubMed ID: 25282404
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Sadri-Vakili G; Cha JH
Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
[TBL] [Abstract][Full Text] [Related]
18. Axonal transport failure in neurodegenerative disorders: the case of Huntington's disease.
Charrin BC; Saudou F; Humbert S
Pathol Biol (Paris); 2005 May; 53(4):189-92. PubMed ID: 15850950
[No Abstract] [Full Text] [Related]
19. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
Ganai SA; Banday S; Farooq Z; Altaf M
Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
[TBL] [Abstract][Full Text] [Related]
20. Huntingtin processing in pathogenesis of Huntington disease.
Qin ZH; Gu ZL
Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
